Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$23.01 - $32.46 $313,028 - $441,585
13,604 Added 12.0%
126,968 $3.05 Million
Q2 2023

Aug 04, 2023

BUY
$29.32 - $35.99 $3.32 Million - $4.08 Million
113,364 New
113,364 $3.62 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Contrarius Investment Management LTD Portfolio

Follow Contrarius Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Contrarius Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Contrarius Investment Management LTD with notifications on news.